Segment Information (Tables)

9 Months Ended

Sep. 30, 2025

Schedule of Reconciliation of Significant Segment Expenses

A reconciliation of the Company’s significant segment expenses to net loss is as follows:


	Three Months Ended September 30,						Nine Months Ended September 30,
(in thousands)	2025			2024			2025			2024
External R&D program expenses:
ARTISTRY-6	$	(4,802	)	$	3,075		$	3,898		$	6,907
ARTISTRY-7		(71	)		4,801			4,778			15,591
Early discovery programs		11			700			5,341			2,142
Other external R&D program expenses(1)		77			8,737			16,217			25,198
Total external R&D program expenses		(4,785	)		17,313			30,234			49,838
Internal R&D expenses:
Employee-related		493			7,635			12,386			24,143
Other internal R&D expenses(2)		4			2,637			3,794			8,016
Total internal R&D expenses		497			10,272			16,180			32,159
Total R&D expenses		(4,288	)		27,585			46,414			81,997
G&A expenses:
Employee-related		980			3,443			6,823			11,170
Other G&A expenses(3)		7,274			3,070			16,469			9,241
Total G&A expenses		8,254			6,513			23,292			20,411
Restructuring expenses:
Employee-related		—			—			9,457			—
Other restructuring expenses(4)		—			—			8,029			—
Total restructuring expenses:		—			—			17,486			—
Other segment (income) expense(5)		(260	)		(2,339	)		(2,367	)		(8,168	)
Segment net loss	$	3,706		$	31,759		$	84,825		$	94,240

(1) Other external R&D program expenses included in segment net loss include expenses related to other clinical trials and general external program expenses.

(2) Other internal R&D expenses included in segment net loss include expenses related to occupancy and depreciation.

(3) Other G&A expenses included in segment net loss include expenses related to professional fees, information technology, depreciation, and other general G&A expenses.

(4) Other restructuring expenses include contract termination costs, impairment and asset write-offs incurred in connection with our reduction-in-force and the termination of certain development programs.

(5) Other non-operating (income) expense included in segment net loss includes interest income, tax expense, and other non-operating income and expense.

Mural Oncology plc 10-Q